Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
Satoru TaguchiTaketo KawaiTohru NakagawaJimpei MiyakawaKenjiro KishitaniKazuma SugimotoYu NakamuraJun KameiDaisuke ObinataKenya YamaguchiTomoyuki KanekoKanae YoshidaSachi YamamotoShigenori KakutaniKoichiro KanazawaYuriko SugiharaMayuko TokunagaAkihiko MatsumotoYukari UemuraYoshiyuki AkiyamaYuta YamadaYusuke SatoDaisuke YamadaYutaka EnomotoHiroaki NishimatsuAkira IshikawaYoshinori TanakaYasushi NagaseTetsuya FujimuraHiroshi FukuharaSatoru TakahashiHaruki KumePublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Patients with aUC treated in the recent era exhibited significantly longer survival than those treated before the introduction of pembrolizumab. The improved survival was primarily attributable to the use of pembrolizumab.